Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis
TPC Dorlo, M Balasegaram, JH Beijnen… - Journal of …, 2012 - academic.oup.com
Miltefosine is an alkylphosphocholine drug with demonstrated activity against various parasite
species and cancer cells as well as some pathogenic bacteria and fungi. For 10 years it …
species and cancer cells as well as some pathogenic bacteria and fungi. For 10 years it …
An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons
EFA Brandon, CD Raap, I Meijerman… - Toxicology and applied …, 2003 - Elsevier
The liver is the predominant organ in which biotransformation of foreign compounds takes
place, although other organs may also be involved in drug biotransformation. Ideally, an in …
place, although other organs may also be involved in drug biotransformation. Ideally, an in …
Clinical pharmacokinetics of therapeutic monoclonal antibodies
RJ Keizer, ADR Huitema, JHM Schellens… - Clinical …, 2010 - Springer
Monoclonal antibodies (mAbs) have been used in the treatment of various diseases for over
20 years and combine high specificity with generally low toxicity. Their pharmacokinetic …
20 years and combine high specificity with generally low toxicity. Their pharmacokinetic …
Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs
AH Schinkel, JJM Smit, O van Tellingen, JH Beijnen… - Cell, 1994 - cell.com
We have generated mice homozygous for a disruption of the mdrfa (also called mdr3) gene,
encoding a drugtransporting P-glycoprotein. The mice were viable and fertile and appeared …
encoding a drugtransporting P-glycoprotein. The mice were viable and fertile and appeared …
[HTML][HTML] Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma
MW Rohaan, TH Borch, JH Van Den Berg… - New England journal …, 2022 - Mass Medical Soc
Background Immune checkpoint inhibitors and targeted therapies have dramatically improved
outcomes in patients with advanced melanoma, but approximately half these patients will …
outcomes in patients with advanced melanoma, but approximately half these patients will …
Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine
A Sparreboom, J Van Asperen… - Proceedings of the …, 1997 - National Acad Sciences
In mice, the mdr1a and mdr1b genes encode drug-transporting proteins that can cause
multidrug resistance in tumor cells by lowering intracellular drug levels. These P-glycoproteins …
multidrug resistance in tumor cells by lowering intracellular drug levels. These P-glycoproteins …
A Phase I and Pharmacological Study with Imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a Novel Ruthenium Anticancer Agent
JM Rademaker-Lakhai, D Van Den Bongard… - Clinical Cancer …, 2004 - AACR
Purpose: NAMI-A {H 2 Im[trans-RuCl 4 (DMSO)HIm] or imidazolium-trans-DMSO-imidazole-tetrachlororuthenate}
is a novel ruthenium-containing compound that has demonstrated …
is a novel ruthenium-containing compound that has demonstrated …
The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria
JW Jonker, M Buitelaar, E Wagenaar… - Proceedings of the …, 2002 - National Acad Sciences
The breast cancer resistance protein (BCRP/ABCG2) is a member of the ATP-binding cassette
family of drug transporters and confers resistance to various anticancer drugs. We show …
family of drug transporters and confers resistance to various anticancer drugs. We show …
Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan
JW Jonker, JW Smit, RF Brinkhuis… - Journal of the …, 2000 - academic.oup.com
Background and Methods: Breast cancer resistance protein (BCRP/MXR/ABCP) is a
multidrug-resistance protein that is a member of the adenosine triphosphate-binding cassette family …
multidrug-resistance protein that is a member of the adenosine triphosphate-binding cassette family …
Approaching tumour therapy beyond platinum drugs: status of the art and perspectives of ruthenium drug candidates
A Bergamo, C Gaiddon, JHM Schellens… - Journal of inorganic …, 2012 - Elsevier
The study of metal complexes for the treatment of cancer diseases has resulted in the
identification of some unique properties of ruthenium-based compounds. Among these inorganic-…
identification of some unique properties of ruthenium-based compounds. Among these inorganic-…